Zoetis: Patience Tested as Headwinds Persist

What happened

Zoetis shares have fallen 37% YTD to a five-year low after rare earnings misses driven by US companion animal weakness, generic pressure, and reduced clinic visits. The company maintained its 2026 guidance for revenue of $9.68–$9.96B and adjusted EPS of $6.85–$7.00, citing upcoming product catalysts. However, the DeepValue report flags persistent risks including Librela safety concerns, competitive threats to core franchises, and decelerating organic growth that may limit near-term upside. Management's ability to protect EPS via cost controls is notable, but top-line momentum remains fragile with OA mAb and livestock weakness likely to persist. The stock trades at ~21x forward EPS, offering a modest margin of safety that requires either a better entry or clearer growth inflection to improve risk-reward.

Implication

Zoetis’s premium valuation and decelerating growth leave limited upside from current levels. While the company retains strong margins and a solid balance sheet, the near-term headwinds from OA franchise weakness and competitive pressures are likely to persist. The maintained guidance provides a floor, but a re-rating higher depends on visible stabilization in OA sales and re-acceleration of organic growth above 6%. Investors should wait for a more compelling entry near $110 or until mid-2026 evidence of a growth inflection. The dividend growth slowdown from 16% to 6% signals management’s realistic view of earnings trajectory, and the stock may remain range-bound until clearer catalysts emerge.

Thesis delta

The narrative shifts from a resilient compounder to a steady but slower grower amid persistent OA and livestock headwinds. The market’s expectation of a quick OA recovery is now challenged, requiring more patience. While guidance holds, the risk of further downgrades has increased, justifying a wait stance.